Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you so much. Good morning and good afternoon, everyone, and welcome to XVIVO Perfusion AB's earnings call for the third quarter of 2026. And we can go to slide number two. Joining me today are Kristoffer Nordström, our CFO, calling in from Denver, Colorado, and myself. Christoffer Rosenblad, CEO, is joining from Stockholm, Sweden today. And with that, we can go to slide number three, which is the Q3 financials at a glance. We delivered another solid quarter with sales in line with the first half of the year and organic growth of 32% compared with the third quarter of 2025. EBITDA remained strong, supporting healthy operating cash flow for the fourth consecutive quarter. Total cash flow was close to neutral, resulting in a stable cash position. Our CFO will later in this call provide more details on sales and gross margin. EBITDA later in the presentation. The business continues to perform very well across both North America and Europe; the positive market trend we saw towards the end of last year continued through the quarter, supported by strong growth in the lung market and our expanding commercial presence. Kidney also delivered strong growth, driven by increased commercial coverage in Europe and growing interest in the US market. Against this backdrop, sales developed this quarter and over the coming quarters will be impacted by the transition to updated core components. While this creates a temporary headwind, it does not change our positive view on the underlying market opportunity and business momentum. Turning to slide four, which is the year-to-date performance. The first nine months of the year show a similar picture to the quarter. We continue to deliver strong and consistent growth, driven by robust performance in Thoracic and healthy growth in Abdominal. Throughout the year, we have continued to invest in our commercial organization, scalable production capabilities, and regulatory approvals to support future growth. Sales amounted to 730 million SEK, corresponding to an organic growth of 30%. A key takeaway from the past two years is that we have demonstrated the scalability of our business model, with only a few months remaining of 2026. We are now increasingly focused on the opportunities ahead. The next two years will be important for us to continue building the company toward our ambition of becoming the preferred partner in the transplant process. Among the most exciting commercial opportunities are the launch of ex vivo transport in Europe and our planned expansion into Canada and Australia. In Australia, ex vivo heart transport has already established a strong position through compassionate use, and has now become the standard of care, which took only three years. And with that, we move over to the next slide. Slide five. And the key business highlights from the quarter are on the following. Slides six and seven. So turning to slide six. And the key highlights from the quarter. Q3 was an important quarter for XVIVO, marked by several milestones across our business. First, with EU approval of XVIVO Heart Assist transport, we can now begin supplying this life-saving technology to patients across Europe. The approval covers all heart types. Donated and all heart transplant recipients, including all age groups as well as both DBD and DCD donors. Clinical data demonstrated a 76% risk reduction in severe PGD. The leading cause of early mortality following heart transplantation. As a result, six additional patients per 100 survive to their one-year follow-up date. This represents a significant benefit for this vulnerable patient population. In addition, XVIVO Heart Assist also has demonstrated the ability to safely extend preservation and transportation times. This gives transplant teams greater flexibility in planning procedures, enabling surgeons to perform under more controlled conditions with rested transplant teams, while also having the potential to reduce the overall cost of the transplant process. Second, we reached another important milestone with the submission of the PMA application for XVIVO Heart Assist in the United States. We are equally committed to patients with end-stage heart failure in the US, and to enabling heart transplant teams to perform surgery with rested teams and in a less stressful and more controlled environment by providing extended transportation capabilities. XVIVO Heart Assist transport has the potential to make more donor hearts available for transplantation while reducing transportation costs, ultimately lowering the overall cost of the transplant procedure. Third, our OPO EVLP hub pilot is now successfully up and running, contributing to the strong lung net sales development we have seen this year. We are now seeing three distinct EVLP models emerging in the US market: advanced transplant centers, centralized EVLP providers, and OPO-based programs. Our strategy is to support all three models, helping more donor lungs reach transplantation and ultimately ensuring that nobody dies while waiting for a lung. Waiting for a lung transplant. To support this development, we continue to invest in our commercial organization and strengthen relationships with an expanding network of EVLP partners across the United States. And finally, the financials. Despite making significant investments in scalable manufacturing, regulatory initiatives, and commercial expansion, we continue to maintain a healthy financial position. We believe this is the right time to invest in long-term growth opportunities ahead of us and continue building XVIVO for the future. And with that, we are turning to slide seven and an update on the European heart launch of XVIVO Heart Assist transport during the quarter. Our primary focus was on preparing the market launch country by country and clinic by clinic across Europe. We are executing a structured three-tier launch strategy. The first phase is now in place, enabling active transplant centers to begin using the XVIVO Heart Assist under derogation or compassionate use while local listing processes are completed. We now turn to tier two, and our current focus is targeting 33 transplant centers across four priority markets where reimbursement is already established. These centers, together with the first eight, represent almost 40% of all heart transplant clinics in Europe. In parallel, our commercial and market access teams are working closely together to identify patient segments where the clinical value proposition is particularly strong, including DCD hearts, long-distance organ transplantation, pediatric transplantation, and complex patients with prior LVAD support. With a very strong clinical evidence base already established, the focus is increasingly shifting towards health economics and reimbursement in Europe. From our perspective, the question is no longer whether the XVIVO heart assist can become the gold standard of future heart transplantation. The key question is how quickly reimbursement can be established to ensure broader patient access across Europe. Ultimately, our ambition is clear: to make this technology available to more patients, enabling more heart transplants and bringing us one step closer to the future where nobody actually dies. Waiting for a heart. So that was the key milestone of this quarter. As we turn to slide eight, we focus on the regulatory and clinical update as more products receive approval and enter the market. The list of ongoing regulatory milestones continues to get shorter. And with that, we can turn to slide nine to show that picture. So the CE-marking for XVIVO heart assist in Europe serves as a foundation for our regulatory application in both Australia and Canada. In addition to the clinical data generated in Australia, the European clinical trial provides strong supporting evidence. It was the first randomized controlled trial with a superiority endpoint conducted in the field of heart transplantation, beyond the strong clinical outcomes. The trial was also the first to establish a link between the preservation method and the risk reduction of severe PGD of 76%, as well as the improved one-year survival of six percentage points for hearts. I will return to a deeper dive in the following slides. And with that, we turn to slide ten. This concerns the regulatory status of the XVIVO heart transport in the United States. The US heart trial was fully enrolled in record time, completing enrollment in 13 months compared to the original plan of 30 months and delivering results consistent with those seen in Europe. The study met its predefined safety and efficacy endpoints, while the analysis of secondary endpoints showed a severe PGD rate of only 7.9%. We also reached an important milestone with the submission of the PMA application for the XVIVO heart assist. The submission was accepted by the FDA in September and the review process is now ongoing. During the quarter, the extension of the Continuous Access Protocol, or the CAP, was also approved, providing access to this innovative and life-saving technology for an additional 60 patients at the participating trial centers in the United States. The Breakthrough Device designation supports an efficient PMA review process, and we are targeting commercial launch in late 2027. This is subject to FDA review process timelines as well as approval. It should be mentioned that the Breakthrough Device designation allows us to have a dialogue with the FDA during the process, so that should facilitate the process. Though I have to mention. As always, FDA review timelines are determined by the agency themselves and remain difficult to predict. We will continue to provide regular updates to the investor community on the progress of the review process during quarterly calls. And with that, we turn to slide 11 and the US Liver Regulatory opportunity. But before I go into that, let me start with an overview of the clinical evidence supporting the XVIVO Liver Assist. Ex Vivo Liver Assist is approaching standard of care for liver transplantation in several European markets and is supported by one of the largest bodies of clinical evidence in the transplant field, if not the largest body of evidence we have seen in the transplant field so far. The evidence base includes more than 100 peer-reviewed publications and covers a broad range of outcomes, from improved patient outcomes in both DCD and DBD liver transplantation to meaningful operational and economic benefits for transplant teams. Clinical studies have demonstrated improved utilization of donor livers, improved post-transplant outcomes, and reduced complications. At the same time, machine perfusion has enabled transplant centers to work with greater flexibility and predictability, supporting both the teams and the hospital operations. Taken together, we believe Ex Vivo Liver Assist has established one of the strongest clinical and health economic evidence bases in transplantation and provides a solid foundation for our regulatory and commercial ambitions in the United States. And with that, we go to slide 12. And a more specific update on the US regulatory pathway for the Liver Assist system following a reevaluation of our US regulatory strategy last year. Interest in the DeLIVER trial has continued to grow among transplant centers in the United States. We are increasingly being approached by centers and clinics that would like to get access to Liver Assist. Recognizing both its clinical benefits and its potential to improve workflow and quality of life for transplant teams, there is a clear demand in the United States for a cost-efficient solution that can improve outcomes while supporting a more sustainable transplant practice. Against this backdrop, our regulatory team is actively preparing the submission package for the FDA. We are targeting a 510(k) submission in the first half of 2027 and, subject to regulatory timelines, a commercial launch in early 2028. We believe the US represents a significant long-term opportunity for Liver Assist, supported by both the strong clinical evidence base we just showed you and the growing market interest. And with that, I turn over to slide 13 and hand over to our CFO. Kristoffer Nordström for the next segment of this quarterly call.
Thank you, Christoffer. So, turning to the financial performance of the third quarter. And this was another stable quarter for XVIVO. As Christoffer already mentioned, net sales reached 253 million SEK, corresponding to an organic growth of 32% in local currencies. Growth was led by Thoracic, our largest business area, while also Abdominal continued to show positive momentum. EBITDA amounted to 52 million SEK, corresponding to a margin of 21% compared with 19% last year. And this improvement was supported primarily by the strong sales, but also somewhat seasonally lower activity levels on the cost side over the summer months. Gross margin is worth a comment. So, gross margin was 70% compared with 75% last year. The year-on-year decrease reflected lower margins in services, as well as product mix and some inventory write-downs within thoracic. Excluding services, where we have made deliberate investments in personnel for some time now, the product gross margin was 75% both in the quarter and year-to-date. Moving over to our largest business area, thoracic. Thoracic delivered a very strong quarter with net sales of 177 million SEK, an organic growth of 51%. Lung sales amounted to 155 million SEK, and EVLP disposable growth was 67% in the quarter, reflecting the continued adoption that we see and the strong activity amongst our larger customers. We mentioned it in the report. So, thoracic also benefited from approximately 19 million SEK of tailwinds towards the end of the quarter. So we had an 8.5 million SEK adjustment, based on IFRS and the treatment of US lease contracts. And that refers to the three OPOs where we delivered SPSS earlier in the year. And now when you do that, you need to take the revenue and the COGS upfront. That is a lesson we learned here in the quarter. So that's why you see a bit of a one-time effect in this quarter isolated. And that is how we are going to treat those contracts going forward as well. When we onboard new OPOs, there was also approximately 10 million SEK of inventory built up by our largest customer in the US. Heart sales amounted to 22 million SEK compared with 10 million SEK last year. The CAP trial has started; I think we had three patients included in Q3. So it contributed 1 million SEK, which means that the rest, 21 million, comes from Europe and Australia, where we continue to see a very strong interest and good adoption of the technology. Gross margin was 80%, compared with 89% last year. And as I mentioned, the decrease is mainly explained by the product mix. Hence, a larger portion of this is X-ray revenue. And also the inventory write-downs. Excluding these events, the gross margin would have been 85% for Thoracic, which is the level we recognize from earlier quarters as well. Moving over to abdominal, net sales of 62 million SEK, corresponding to an organic growth of 12%. DeLIVER sales were 40 million SEK and grew 9% in local currencies. Growth was somewhat lower than last year, reflecting temporary implications from the manufacturing transfer that has been going on, and somewhat softer activity in a few European markets over the summer. We remain encouraged by the long-term opportunity, supported by continued adoption in our core markets and the broader utilization that continues, but also more long-term, the reimbursement developments and those opportunities. Kidney sales amounted to 22 million SEK and grew 19% in local currencies. Growth in the quarter was affected by seasonality and implications from the manufacturing transfer as well. And we believe that will continue into Q4. We do expect growth at current customers and with the current design to continue and to return to higher levels of growth from the beginning of 2027. Gross margin was 61% compared with 60% last year. Turning to services, our final business area. So net sales were 14 million SEK. That means a negative growth of 28%. The decline was again primarily explained by lower organ recovery volumes. We remain optimistic about the pipeline of prospective customers. We have several contract processes currently underway. That's very encouraging. However, these processes continue to take longer than we anticipated to convert into revenue. Gross margin was 19% compared with 37% last year. The decrease reflects the lower recovery volumes combined with our investment in expanding the surgical team to position us for winning new contracts in new geographies and for building capacity ahead of the US heart launch later on. As recovery volumes increase and the new capacity is utilized. We expect the gross margins to recover significantly. EBITDA was 52 million SEK in Q3 compared with 36 million SEK last year, and the EBITDA margin improved to 21% from 19% year to date. EBITDA was 148 million, and the margin was 20% compared to 17% last year. So an improvement there on a rolling 12-month basis. We are at 21%. The margin improvement in the quarter was supported by the strong sales, but also the seasonally lower research activity. While we continue to invest in commercial expansion, we talked about regulatory activities and also the infrastructure to support the future growth. Final slide. Cash flow from operating activities was strong, 53 million SEK positive in the quarter, compared with 21 million last year. The improvement was primarily driven by the strong sales development, and for the first nine months, our operating cash flow amounted to 182 million SEK, compared with only 14 million SEK last year. So a significant improvement on the cash flow this year, which I am very proud of. Cash flow from investing activities was -49 million SEK, and 39 million of those were invested into our regulatory approval processes and clinical trials, primarily related to heart. So over the past three quarters, we have generated positive operating cash flows. That has been sufficient to fund both our operating and our investing activities. And we ended the quarter with a cash position of 313 million SEK. In addition, we have an unutilized part of our credit facility of €12 million. So we believe that we will enter next year with a solid cash position. With those comments, Christoffer, I will hand over to you again. Thank you.
Thank you for that. We are now at the last section of the presentation, the outlook session, and looking into the next couple of years, we can turn to slide 21. Our outlook for the remainder of 2026 and the next two years: over the past four years, we have invested heavily in building XVIVO into the company we are today. Today, we are second to none in innovation. We are number one in customer support and clinical evidence within transplantation. So, we have built a strong position, combining those with the close partnerships with transplant teams around the world. This has created a strong foundation for very high continued growth into the future. All of our major product platforms are now CE-marked in Europe, and we are making good progress toward achieving the same in the US. As we look ahead, our focus increasingly shifts from building capabilities to expanding access and driving adoption of our products. Our ambition is to become the preferred partner in the transplant process. To achieve that, we have identified four key pillars or priorities. And number one is to secure market access for heart and liver in the US through regulatory approval, reimbursement, continued generation of US clinical evidence, and further development of decision support parameters for both heart and livers with the HOPE. Priority number two is the exciting ex vivo heart launch in Europe. Our aim is to establish the ex vivo Heart Assist transport as a standard of care for modern transplantation. Third, we will continue to strengthen our leadership position in EVLP for lungs. We will continue to work closely with transplant centers to advance the science of lung transplantation. We continue to support pump centers and we continue to support OPOs and centralized evaluation hubs in increasing access to donor lungs for transplant programs across the United States. And finally, we continue to invest in a robust and scalable supply chain, maintaining the highest standards of quality across our products and processes. We are growing very fast and we have to make sure that our supply chain runs equally fast. In addition, to maintain our number one position in perceived quality of customer support, we will continue investing in our commercial capability and in the partnerships that are critical to the success of transplant programs across the world. The opportunities we see ahead of us are significant. We have a strong product portfolio, growing clinical evidence, and dedicated teams around the world. We believe that XVIVO Perfusion AB is well positioned for the next phase of our growth journey. And with that, we can turn to slide 22 and our longer-term outlook. Because if we look at the longer term, the fundamental picture remains unchanged. And in many ways, this is also the reason we are all here today. According to the WHO. The demand for organ transplantation remains approximately ten times greater than the available supply of donor organs. At the same time, the value created through machine perfusion is significantly higher than with traditional static cold storage. Clinical evidence and real-world experience have demonstrated that a machine perfusion service model can increase organ utilization, particularly within the rapidly growing DCD donor pool. The key drivers are superior clinical outcomes, increased utilization of donor organs, and simplified workflows for the transplant center. As a result, we believe machine perfusion and service-based models for both DBD and DCD organs will continue to drive growth in transplantations for many years to come. At XVIVO, our ambition is to change the paradigm of transplantation through innovation. We are committed to improving life after transplantation, making more organs available for patients in need, and providing transplant teams with technology that enables surgeons to perform under the best possible conditions. And therefore, our vision remains unchanged, that nobody should die waiting for an organ. And with that, we can turn to slide 23. And before we open up for questions, I just want to touch base on a few points. Our dream, and what we have been working the last ten years to achieve, is for transplantation to become a standard procedure. And that organ transplantation can be performed using ordinary modes of transportation, and that it should be done by the transplant teams with the best possible patient outcome. So again, next time when you are out flying, I hope that you are seated next to one of our device sets on a flight. And remember, it is not just a device being transported; it is a donor heart going to a patient whose life is about to change. And I want to thank you all for supporting this journey with us. And with that, I want to also thank you for listening today. And we will now open up the line for questioning.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Jakob Lemke from SEB. Please go ahead.
Yes. Hi. Good afternoon. My first question is on heart and maybe shortly if you could share the split between Europe and Australia for the Q3 sales. And then also if we could come. If you are already starting to drive adoption among these tier one compassionate use centers, and also when you will start to onboard new customers in that tier two category.
Thank you. I will start with the second question. We are listing the product, so we are targeting to onboard new customers in December of this year. We know the listing process is 3 to 4 months. So right now, the sales we see on heart are still coming from compassionate use.
I can follow up on the first question. So, for Q3, heart sales were as follows: Australia and New Zealand 9 million SEK, Europe 11 million SEK, and US CAP study 1 million SEK. Thank you.
Okay, good. If I understand correctly, are you growing your volumes with these existing customers right now, or are those volumes stable?
That is a good question. The majority of centers are growing. But we still believe that the real growth from both new centers and existing centers will come with the listing of the product, selling on the CE-marking, and with reimbursement kicking in. Hence, as of December.
Very clear. Then on liver in the US, it is very good that you are targeting a faster launch here. I am wondering how you see the long-term prospects in the US market. On the one hand you are very strong in Europe, but the US market is also more crowded. And there are already two warm perfusion players and one cold perfusion. So it would be interesting to hear what you think about the long term in the US.
That is a great question. I mean, from customer feedback, it has been very clear that they need an alternative in the US. And when transplant surgeons and transplant coordinators all meet at larger global conferences, it is clear that they recognize the need. When they see Europe, it is clear that they see an extremely good, very stable product with the best clinical results in the world. So, of course, they want to get their hands on that one. We are realizing it is a more crowded field. And I think the success rate of it will depend partly on how fast we can afford to scale up sales and support functions to deliver assist, which will be key to being successful in the United States, as well as partnerships within the, let's call it, logistics perfusionist area. So we can support OPOs in pumping the greatest number of livers as possible. So there will be some investment needed, and some partnership discussions needed to have the greatest possible success.
Do you think that you will mainly convert customers that today are on warm perfusion solutions? Or will it be those that do not use perfusion at all, or those converting now, or perhaps those currently using static preservation? Do you have any sense of that? Which do you see as your main opportunity?
We are performing that work right now to assess what the main opportunity will be. I think that we will see opportunities in all of the above, then depending on how fast we can change current behavior, that will be the leading cause to where we will get the highest uptake of our technology. But as always, when you launch a product, I think the majority of sales in the beginning will come from the visionaries, the ones who want to change. And over time, that will trickle down to the majority market.
Good. Then I also have a question on this stocking. You mentioned your large customer in the US. Just to understand, is this an order you otherwise would have expected in Q4 that now came in in Q3? Or is it that sales stand out as unusually high to the customer. Just some more color on that, please.
It is. Yeah. Given our insight into the volumes, this was more of a top-up as we see it. So we are concerned that it could mean the sales in Q4 to this specific customer might be slightly less than we expected, but still solid and contributing to growth in Q4.
A short comment on that one. Sometimes when we get orders, they can fall on the last day of one quarter or the first day of another quarter. This fell on the last day. It happens. It is not unusual. We just want to be very transparent.
Okay, good. That is very helpful. Then a final question from my end is on kidney. And if you can elaborate a bit on what you mean by moderate growth, let's say, do you still see some growth? Will you go with existing accounts or will you also take on some new accounts, or how should we look at that?
No, that is a good question. That needs some clarification. We see high growth opportunities in the US coming from both existing but primarily new accounts in the United States as well as Europe. So we are talking about moderate growth, probably around 30%, but the opportunity is much higher. If I look into the pipeline of new kidney customers, especially in the US market, but also in Europe, we have had, so far, far above 60% growth here in Europe. However, due to some component changes, we are experiencing a shortage situation. We need to allocate them wisely and we will not be able to fulfill the full demand of the market next year. In kidney. That is our best estimation. But we still have solid growth, but unfortunately not to its true potential, which we would have hoped.
Okay. That's that's very helpful. Thank you very much for taking my questions.
Thank you.
The next question comes from Simon Larsen from Danske Bank. Please go ahead.
So let's see. Hopefully you can hear me better now. Yes, I would like, perfect. I would like to start on this big US lung customer. And you are of course mentioning again in the report that they are planning to switch at least partly to their own EVLP platform here in 2027. And just for our benefit, to help us think about the dynamics in that switch. Will this be from one day to another? Will it be more of a gradual shift? Because I am thinking that some of the customers might just stick to your platform, given that they have experience working with it. So any color on that dynamic would be helpful.
Thank you. We will try our best. But you have a point that there is an end customer who has a say in this one. And it is very clear that the customer decides. Just to be very clear, we've been partners for more than ten years. And we are in constant dialogue around how to increase the lung utilization rate in the United States, which today is around 20%. It should be 50%. The jump from 20% to 50% is the goal, as that is what the technology is developed for. So we are looking into those two at the same time. We are in a phase in the dialogue where we cannot go into exactly how the dynamic of pricing will develop. But we will, as soon as we know, inform the investor community, at the latest in the quarterly report for Q4.
That is clear. And maybe a bit of a conceptual question, but when we are looking into next year and on lung specifically, okay, we have this, let's call it a headwind, potentially from this specific customer, but you had a very strong placement year last year of XPS systems. The OPO model is starting to bear fruit. Is it plausible for those initiatives to counteract to a full extent the potential headwind from the biggest customer, or is the magnitude too big to counteract, or how should we think about the whole lung franchise next year in terms of growth rates? Yes, maybe high level takes from your end.
Great. Yeah. I will provide a high-level answer to that one. And we need to come back with a more detailed answer. But we do see fast growth in our new customers. And we do believe that that will hopefully cover any shortfall. So that is our strategy. And we need to, of course, come back and update you regularly every quarter next year on the case. But that is the working hypothesis right now.
Lovely. Maybe my final question on services: are you evaluating any type of restructuring of that business or any similar initiatives? Do you think it is crucial for XVIVO Perfusion to have an in-house service capability over time, or would it be more cost-effective to work with a partner instead? Or what is your thinking about that business area right now?
To answer more generally, we are continuously evaluating our strategy and go-to-market strategy for all of our products. As we have mentioned many times, this was bought as an option for the US heart launch, and we are now nearing the US heart launch. So of course, we are looking into what is the best possible way to ensure we have the best quality organ recovery service. It is a great asset that we will use in the heart launch either way. But of course, we are looking into any strategic opportunities constantly to see what is the best way forward.
I also want to comment that the restructuring, as you mentioned, is what has occurred. And that is also why we have invested in this business. And that is currently weighing down the margins of that business. But it has been a deliberate decision, and the restructuring has been attracting very talented surgeons in strategic geographies to position us for winning new contracts and to be in a good spot when we launch the heart product. I am very excited about the contracting discussions we have at the moment. And I just wish it went faster, so to say. But we will get there.
Understood. Perfect. Thank you very much.
The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.
Hi. Good afternoon. I have a few questions today. I think I will start on liver. So I am a bit curious about the submission process in the US. So what exactly does it take before you can submit it, as you have targeted? Now I have a 2027 target. So what are you going to do until then; is it mostly just writing it up? Or will you need to get any sort of clinical data? I think you noted on the slide that you are going to submit based on data from outside the US. So, do you have everything you need currently? Yeah.
Thank you for that question. Of course, setting up the file and application will take some time, and that is where we will spend our efforts; our current strategy is that we will use outside data, although the usability validation still needs to be done in the United States, but that is not a clinical trial. It is more of a usability trial. So that also takes some time. So that is what we will spend the majority of the time on until submission.
Okay. I think you have spoken before because the predicate device you are relying on now is just HOPE. But you have most of your data in the HOPE, but you have sufficient data for submission. It seems like that.
Yes. That is our view. We believe that we have data both on HOPE and DHOPE.
Okay. Okay, good. A very simple answer, then. I was just moving on to services. You have spoken about that. You've anticipated some kind of turnaround, but it hasn't turned up yet. It seems that finalizing contracts is taking a longer time. Are there any reasons to be more optimistic now in 2027? You said you have some in the pipeline, but how reasonable is it to expect growth? Would you say so?
It is very reasonable to expect growth in 2027. Not necessarily in Q4. Because it takes some time with the contracting, with legal and IT and all that stuff. But we are very far along on very interesting opportunities. So, I am confident we will see growth in 2027.
Okay. Thank you. And perhaps my last question is regarding the costs for next year. So now, you will have the US heart launch toward the end of next year. And then you also have liver in the US, and you continue ramping up heart. So how should we think about costs ramping up next year? Do you think you will be able to defend the margins that you have achieved this year? Or how should we think about it?
That is a great question. It is slightly dependent on the timing of approvals. So we will invest in a larger sales force prior to approval. Through the study and the continuous access protocol, we already have customers up and running in the United States. So we believe that over time, over quite a short period of time, we will regain that. But we would need to invest a little bit before approval. So everybody is up and running and we can do a great launch. But fast recovery of those costs and how we invest will depend on the timing of approval.
Okay. But if the current plan plays out as you believe, with heart launch and liver launch. Beginning of 2028. I suppose you will have to invest next year, but do you think you can defend the margin that you have this year then?
I think that we will see a slight margin dip during the second half of the year due to the investment in an increased sales force for both heart and liver.
Okay, great. I'll take that answer. Thanks very much. That was all from me.
The next question comes from Ludwig Germain from Handelsbanken. Please go ahead.
Yes. Good afternoon. Thanks for taking my questions. I want to start with another question on heart, similar to one that has already been asked, but I guess a little bit different. So, about the tier one and tier two centers that you were talking about. If I understood you correctly, you are currently, as of today, still running on compassionate use, but as I understand it, you are still fully up and running with the tier one centers. So the first question is around the tier one centers. Do you view them to be fully up and running in terms of their capacity? Or do you see more growth at each center going forward? And the second question on this topic would be, how long do you expect the initial tier two rollout to take? So basically, from the date you start with the tier two centers to today, have you reached the first group?
Thank you for that question. If we look at tier one centers, they are not fully up and running. There is a lot of potential in each account, in each of the eight, still. If I parallel that to the Australian launch where we had year one at the end of the first year after launch, I think we had 30% penetration going into year two. Then in year three, up to 50% and above. And we actually reached up to in a few centers, more than 60%. So we will see a similar development in each account in Europe. Well, the question of how fast it will be at this point, we are modeling this one, but it will be quite central depending on how they will approach it and how fast the reimbursement kicks in. As I said in the call, we believe that this will become the gold standard. This is how you transport hearts, but it will depend on reimbursement in every country. So we are more looking into how fast we can establish reimbursement. We haven't heard any customer so far who said, we don't want to use this product. It is more that when it is reimbursed, I will use it for half of my heart transplants or all of my heart transplants. That is the conversation we have.
Yeah. Got it. Thank you. And then one more on lung. You have been talking about dimensioning the inventory buildup from your customer. But I am just thinking about bridging into Q4 here. If we assume a sort of underlying lung pace and just adjust for this inventory buildup in Q3, should that take us close to what's reasonable to expect for Q4? Or are there other moving parts to be aware of when it comes to the sequential development here?
To my knowledge, there are no other moving parts for Q4.
Great. And then my final question on this leasing effect that we saw in the quarter, could you just give us some more color about the timing here? Because I thought that HOPE had been up for a few quarters before this. What is the reason for the timing of this to hit now? Or is this something that has been in the numbers before, but you just mentioned it for the first time now.
Yes. Valid question. So this relates to the HOPE model where we are not selling a device, but we are placing a device with a lease contract over two years to our perfusion partner. When we placed the first HOPE in Q4 last year, and since it was a very small business, we treated it as you know, taking the revenue on a monthly basis in connection with our invoicing. But now that this business has grown, we have looked into it further with our auditors, and it has been clear that this qualifies as a financial lease agreement, where you should recognize the full value of the contract on day one. So since we did not do that retroactively, we needed to take revenue for these three HOPE placements in one quarter retrospectively with the associated costs as well. So that is the reason. So it is a catch-up, so to speak. And in the future, when we have a new HOPE placement, you will see the full revenue. I think it is around 4 million in that quarter. Is that clear?
Yeah. It is clear, just to make sure we get the full picture, is this contract? And the value that you account for, is that for the? And yes, they can continue to use the machine; that will be recorded as sales.
Oh yeah. Yeah. It is a razor blade model as always. But this is only for the machine. So this was the leftover revenue for three machines that we placed earlier in the year.
To be clear, we are trying to communicate the underlying revenue. So it will be for the heart or kidney kitsets. This IFRS reporting, whether it is an operational or financial lease, I honestly do not care about. It is every time we use the machine, we save another life. And we take somebody off the waiting list. So that's what we communicate for transparency reasons; we want to be very transparent regarding this change from operational to financial leases, but it's more of an IFRS matter and has nothing to do with the underlying business.
Of course, I appreciate the transparency, and it is very clear now. Thank you. That's all for me.
Thank you.
The next question comes from Elvin Rohleder from DNB Carnegie. Please go ahead.
Good afternoon, Christoffer and Kristoffer. I have just two questions. There has been a lot discussed already, but perhaps we can dig more into this OPO model. You said you have three OPOs online now, and I believe in Q2 you talked about additional OPOs that you have line of sight on. Regarding this model, can you elaborate on how that pipeline is developing and how we should expect the number of OPOs to progress in the coming quarters?
Thank you. That's a great question. We have identified five or more OPOs in the pipeline that we will gradually introduce to this concept. The interest is very high. It simplifies the process. It reduces the overall cost, and it helps the OPOs to improve their metrics, which is the usage rate of lungs. It is a great method. The key here is to do the implementation flawlessly so it can be up and running as soon as possible. So it will be, if you call it, a controlled build up of the pipeline in the next couple of quarters to make sure we have the best success we possibly can.
Uh, great. Thank you. And then maybe you touched upon it previously. We have talked a lot about liver during the call, but I guess I want to hear more about your rationale behind going for 510(k) with the more narrow HOPE label compared to the DHOPE, given the fact that you also have the heart launch in the US up and running. How should we think about the degree to which you invest in liver on a HOPE label basis in the US, also coupled with the fact that there is an approved HOPE product there and that competitors raised money recently and will probably move into their commercialization. So how should we view those competitive dynamics for liver?
We acknowledge the liver is definitely a competitive market. We believe that the body of evidence we have is second to none for liver. So we believe we have a bit of a head start there. We also have an abdominal team up and running already with kidney. So, we do think that there are investments, but compared to the investments we've seen other parties make, we don't think we're even close to needing that type of investment to be very successful in this market.
Okay, great. Maybe just a final one from me. There was, apart from your largest US lung customer, having their model approved. There is also another company that had their device for EVLP approved, so it has been a couple of months now. I guess it is still early days for that company, but can you comment on whether or not that has affected competitive dynamics within lung in the US?
So far, we haven't seen that the competitive dynamics have changed in any way. It is still early days. We do expect, if we look at the numbers, that approximately 20% of all lungs are used. And today, 2 to 3% of those come from EVLP. So, and we know we're going to grow from 20% to 50%. So the market opportunity is another 30 percentage points. And they will all come from EVLP because they need evaluation. So there is a lot of work to be done having more entrants into the market. There are two effects. There is some competition, but there are also more companies talking about the ability to evaluate more lungs for transplantation. So we do believe that the market growth will increase over time due to more players in this field.
Okay, great. Thank you. I think that was all from my side. Thank you for taking my questions.
Thank you so much. We are nearing the end of this meeting. Are there any questions left?
The next question comes from Ed Hall from Stifel. Please go ahead.
Hi there. Thanks for taking my questions. I'll keep it short. Just on the, I think I misheard on the quantifying the largest US customer share. If you could break that down, that would be helpful. And looking forward, excluding that customer, how should we think about the disposable growth, specifically the contribution from OPOs versus existing accounts. Thanks.
Great. Thank you. To start with, I will answer the second question. And you can answer the first one. We see very solid growth from all our customers, and I believe year-to-date we are at 92% growth. I would focus on disposables and not IFRS effects or anything else. Or stocking. So we see solid growth. We think that will continue with the addition of more accounts and with growth within existing accounts. So we do see a very solid pipeline, great interest, and that is converted into high sales growth.
Yeah. Looking at the annual report from last year, we can see the figures. So we disclosed there under revenue that the largest customer last year in the US totaled 132 million SEK in 2025. I think that is a good measure for the magnitude.
Okay. Perfect. Thank you very much.
Thank you. Did you have any more questions?
I guess maybe just one more on the static cold storage growth. I know we've talked a lot about your expectations for this going forward.
Yeah. We have a dominant market share in static cold storage for lungs. It is the gold standard. It is used by more or less every country in the world today, except where we choose to not sell it for ethical reasons. So we expect to grow with market growth that, if I remember correctly, we have in our plans right now is roughly 5% for next year. Yeah.
Take care. Thank you very much.
Thank you so much. With that, we unfortunately have to end this call. And we are inviting you back for the year-end report 2026. That call will be held on January 28th, 2027. So until then, I wish you a very good time and hope to see you back for the Q4 or year-end report. Thank you everyone.



















